Who is sponsoring NCT04524858?

NCT04524858 is sponsored by Aclaris Therapeutics, Inc..

What drugs are being tested in NCT04524858?

Interventions in NCT04524858: ATI-450.

What condition does NCT04524858 study?

NCT04524858 studies Cryopyrin-Associated Periodic Syndrome.

Is NCT04524858 still recruiting?

NCT04524858 is currently terminated. Last updated 21 September 2023.

Are results published for NCT04524858?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2023-09-21 · How we verify

NCT04524858

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of ATI-450 in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS)

Terminated Phase 2 Results posted Last updated 21 September 2023

What this trial tests

Phase 2 trial testing ATI-450 in Cryopyrin-Associated Periodic Syndrome in 1 participant. Terminated before completion.

Timeline

23 October 2020

Primary endpoint
25 February 2021

25 February 2021

Quick facts

Lead sponsor	Aclaris Therapeutics, Inc.
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	1
Start date	23 October 2020
Primary completion	25 February 2021
Estimated completion	25 February 2021
Sites	2 locations across United States

Drugs / interventions tested

ATI-450 — full drug profile →

Conditions studied

Cryopyrin-Associated Periodic Syndrome — all drugs for Cryopyrin-Associated Periodic Syndrome →

Sponsor

Aclaris Therapeutics, Inc. — full company profile →

Who can join

18 and older, any sex, with Cryopyrin-Associated Periodic Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase 2 study to investigate the safety and efficacy of ATI-450 for the Maintenance of Remission in Patients with Cryopyrin-Associated Periodic Syndrome (CAPS) Previously Managed with Anti-IL-1 Therapy.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Diversity and versatility of p38 kinase signalling in health and disease.
Canovas B, Nebreda AR. · · 2021 · cited 466× · PMID 33504982 · DOI 10.1038/s41580-020-00322-w
IL-1 and autoinflammatory disease: biology, pathogenesis and therapeutic targeting.
Broderick L, Hoffman HM. · · 2022 · cited 112× · PMID 35729334 · DOI 10.1038/s41584-022-00797-1

Verify or expand the search:

Other trials of ATI-450

Trials testing the same drug.

NCT05511519 — Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic Arthritis · Phase 2 · terminated
NCT05216224 — ATI-450 vs Placebo in Participants With Moderate to Severe Hidradenitis Suppurativa (HS) · Phase 2 · completed
NCT04481685 — A Trial of Aclaris Therapeutics, Inc. (ATI)-450 in Patients With Moderate-severe Novel Coronavirus Disease 2019 (COVID-1 · Phase 2 · completed
NCT04247815 — Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA · Phase 2 · completed

Other Aclaris Therapeutics, Inc. trials

Trials by the same sponsor.

NCT06585202 — Study of ATI-2138 in Adult Participants With Moderate to Severe Atopic Dermatitis · Phase 2 · completed
NCT05511519 — Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic Arthritis · Phase 2 · terminated
NCT05432596 — Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic Dermatitis · Phase 2 · completed
NCT05279417 — ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Participants With Moderate to Severe Active Rheumatoid Arthri · Phase 2 · completed
NCT05216224 — ATI-450 vs Placebo in Participants With Moderate to Severe Hidradenitis Suppurativa (HS) · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04524858 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Aclaris Therapeutics, Inc.
Last refreshed: 21 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04524858.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing